文献速递生殖医学

多囊卵巢综合征女性接受卵胞浆内单精子注射时补充肌醇:随机对照试验的系统评价与Meta分析

Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Reprod Biomed Online · 2017-07-14

该系统评价与Meta分析纳入8项随机对照试验共1019例多囊卵巢综合征女性,评估肌醇联合促排卵药对比单用促排卵药对卵母细胞质量、胚胎质量和妊娠率的影响。结果显示,补充肌醇未能改善卵母细胞质量(OR 2.2051;95%CI 0.8260至5.8868)、胚胎质量(OR 1.6231,95%CI 0.3926至6.7097)或妊娠率(OR 1.2832,95%CI 0.8692至1.8944)。作者认为,未来需要设计合适的DCI剂量、样本量和持续时间的研究来明确其在PCOS管理中的作用。

要点

  • 补充肌醇未能改善PCOS女性ICSI后的卵母细胞质量(OR 2.2051;95%CI 0.8260至5.8868)。
  • 补充肌醇未能改善胚胎质量(OR 1.6231,95%CI 0.3926至6.7097)。
  • 补充肌醇未能改善妊娠率(OR 1.2832,95%CI 0.8692至1.8944)。

核心结论

  • 补充肌醇不足以改善PCOS女性接受ICSI时的卵母细胞质量、胚胎质量或妊娠率。
  • 未来需要设计合适的DCI剂量、样本量和持续时间的研究来明确其在PCOS管理中的作用。

研究设计与样本

  • 系统评价与Meta分析,检索Web of Knowledge、MEDLINE、EMBASE、Pubmed、Scopus和Cochrane数据库截至2017年3月发表的所有语言文章。
  • 纳入标准为:人群为PCOS患者;干预为肌醇(MYO、DCI或两者,任意剂量和任意持续时间)联合促排卵药对比单用促排卵药;结局为卵母细胞和胚胎质量;研究设计为随机对照试验。
  • 从76项已识别研究中纳入8项随机对照试验进行分析,共包含1019例PCOS女性。

主要发现

  • 补充MYO未能改善卵母细胞质量(OR 2.2051;95%CI 0.8260至5.8868)。
  • 补充MYO未能改善胚胎质量(OR 1.6231,95%CI 0.3926至6.7097)。
  • 补充MYO未能改善妊娠率(OR 1.2832,95%CI 0.8692至1.8944)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未来需要设计合适的DCI剂量、样本量和持续时间的研究来明确其在PCOS管理中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polycystic ovary syndrome (PCOS) is a complex and heterogeneous disease that involves menstrual dysfunction and reproductive difficulty, as well as metabolic problems. The aim of this study was to assess the effectiveness of myo-inositol (MYO) and d-chiro-inositol (DCI) on improving oocyte or embryo quality and pregnancy rates for women with PCOS undergoing intracytoplasmic sperm injection (ICSI). We searched the Web of Knowledge, MEDLINE, EMBASE, Pubmed, Scopus and Cochrane databases for all articles published in any language up to March 2017. The selection criteria were as follows: (population) patients with PCOS; (intervention) treatment with inositol (MYO, DCI, or both, with any dose and any duration) in conjunction with an ovulation-inducing agent versus the ovulation-inducing agent alone; (outcome) oocyte and embryo quality; (study design) randomized controlled trials. Of 76 identified studies, eight RCTs were included for analysis comprising 1019 women with PCOS. MYO supplementation was insufficient to improve oocyte quality (OR 2.2051; 95% CI 0.8260 to 5.8868), embryo quality (OR 1.6231, 95% CI 0.3926 to 6.7097), or pregnancy rate (OR 1.2832, 95% CI 0.8692 to 1.8944). Future studies of appropriate dose, size and duration of DCI are vital to clarify its the role in the management of PCOS.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Mendoza N, Pérez L, Simoncini T, et al. Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials. Reprod Biomed Online. 2017. PMID: 28756130. doi:10.1016/j.rbmo.2017.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。